Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
Prayer-Galetti
Tommaso
T
Department of Urology, University of Padova, Padova, Italy. tommaso.prayer@unipd.it
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000235:genetics* / Q000378:metabolism; D019943:Amino Acid Substitution; D018890:Chemoprevention; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors; D014644:Genetic Variation; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms; D017211:Treatment Failure
D004791:Enzyme Inhibitors; D042944:Cholestenone 5 alpha-Reductase; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase